ACCUiN Next Generation Pharmacogenomics Gene Analysis Panel
ABCG2, ADD1, APOE, CES1, CYP2C19, CYP2C9, CYP2D6, CYP4F2, SLCO1B1, and VKORC1 gene specific variants
.png)
ACCUiN Next Generation Pharmacogenomics Gene Analysis Panel
Product Introduction
ACCUiN Next Generation Pharmacogenomics Gene Analysis Panel is a qualitative detection designed using Multiplex polymerase chain reaction (Multiplex PCR), requiring next-generation sequencing system (NGS) to detect whether test samples have specific gene variants. ACCUiN Next Generation Pharmacogenomics Gene Analysis Panel can be used to detect specific variants in ABCG2 (NM_004827), ADD1 (NM_001119), APOE (NM_000041), CES1 (NM_001025195), CYP2C19 (NM_000769), CYP2C9 (NM_000771), CYP2D6 (NM_000106), CYP4F2 (NM_001082), SLCO1B1 (NM_006446), and VKORC1 (NM_024006) genes. ACCUiN Next Generation Pharmacogenomics Gene Analysis Panel has passed quality validation and functional verification to ensure performance stability and reproducibility. ACCUiN Next Generation Pharmacogenomics Gene Analysis Panel can provide at least 48 detection reactions.
Specifications
- PGX-48A: Index 1-24
- PGX-48B: Index 25-48
- PGX-48C: Index 49-72
- PGX-48D: Index 73-96
- Reaction quantity: 48 reactions
- Detection target: ABCG2, ADD1, APOE, CES1, CYP2C19, CYP2C9, CYP2D6, CYP4F2, SLCO1B1, VKORC1 gene specific variants
- Detection method: Multiplex PCR + NGS
- Sample type: Whole blood, saliva, oral mucosa
Simple Flowchart
.png)
.png)